Trinity Biotech plc Drops 9.77% After Reverse Stock Split

Trinity Biotech plc (TRIB) experienced a significant drop of 9.77% in pre-market trading on August 21, 2025.

Trinity Biotech recently performed a 1 for 5 reverse stock split, which means shareholders now hold 1 share for every 5 shares previously held. This move is part of the company's strategic efforts to enhance its financial performance and market positioning.

The company has received regulatory approval to commence offshore and outsourced manufacturing of its flagship TrinScreen™ HIV rapid test. This strategic move is expected to enhance the company’s financial performance by expanding gross margins, freeing up working capital, and reducing fixed costs, thereby supporting broader profitability and growth objectives. The transition to a more cost-effective and scalable production model marks a critical milestone in Trinity Biotech’s transformation strategy, positioning the company for long-term financial health and improved industry positioning.

Trinity Biotech is a commercial-stage biotechnology company specializing in human diagnostics and diabetes management solutions, including wearable biosensors. The company develops, acquires, manufactures, and markets diagnostic systems for point-of-care and clinical laboratory segments, and has recently ventured into the wearable biosensor market with the acquisition of Waveform Technologies Inc.’s biosensor assets. Trinity Biotech’s products are used to detect infectious diseases and measure Haemoglobin A1c levels, among other chemistry parameters, and are sold directly in the United States and through international distributors in over 75 countries.